Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Twelve-Year Survival in a Patient With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension on Nifedipine Monotherapy.

Helgeson SA, Enderby CY, Moss JE, Gass JM, Zeiger TK, Burger CD.

Mayo Clin Proc Innov Qual Outcomes. 2019 Jul 19;3(3):376-379. doi: 10.1016/j.mayocpiqo.2019.06.002. eCollection 2019 Sep.

2.

Low-dose sirolimus in retroperitoneal lymphangioleiomyomas.

Ussavarungsi K, Laroia AT, Burger CD.

Lung India. 2019 Jul-Aug;36(4):349-352. doi: 10.4103/lungindia.lungindia_433_18.

3.

Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies.

Benza RL, Gomberg-Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE, McGoon MD, Pasta DJ, Selej M, Burger CD, Frantz RP.

Chest. 2019 Aug;156(2):323-337. doi: 10.1016/j.chest.2019.02.004. Epub 2019 Feb 14.

4.

Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases.

Mira-Avendano I, Abril A, Burger CD, Dellaripa PF, Fischer A, Gotway MB, Lee AS, Lee JS, Matteson EL, Yi ES, Ryu JH.

Mayo Clin Proc. 2019 Feb;94(2):309-325. doi: 10.1016/j.mayocp.2018.09.002. Epub 2018 Dec 14. Review.

PMID:
30558827
5.

Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis.

Rhodes CJ, Batai K, Bleda M, Haimel M, Southgate L, Germain M, Pauciulo MW, Hadinnapola C, Aman J, Girerd B, Arora A, Knight J, Hanscombe KB, Karnes JH, Kaakinen M, Gall H, Ulrich A, Harbaum L, Cebola I, Ferrer J, Lutz K, Swietlik EM, Ahmad F, Amouyel P, Archer SL, Argula R, Austin ED, Badesch D, Bakshi S, Barnett C, Benza R, Bhatt N, Bogaard HJ, Burger CD, Chakinala M, Church C, Coghlan JG, Condliffe R, Corris PA, Danesino C, Debette S, Elliott CG, Elwing J, Eyries M, Fortin T, Franke A, Frantz RP, Frost A, Garcia JGN, Ghio S, Ghofrani HA, Gibbs JSR, Harley J, He H, Hill NS, Hirsch R, Houweling AC, Howard LS, Ivy D, Kiely DG, Klinger J, Kovacs G, Lahm T, Laudes M, Machado RD, MacKenzie Ross RV, Marsolo K, Martin LJ, Moledina S, Montani D, Nathan SD, Newnham M, Olschewski A, Olschewski H, Oudiz RJ, Ouwehand WH, Peacock AJ, Pepke-Zaba J, Rehman Z, Robbins I, Roden DM, Rosenzweig EB, Saydain G, Scelsi L, Schilz R, Seeger W, Shaffer CM, Simms RW, Simon M, Sitbon O, Suntharalingam J, Tang H, Tchourbanov AY, Thenappan T, Torres F, Toshner MR, Treacy CM, Vonk Noordegraaf A, Waisfisz Q, Walsworth AK, Walter RE, Wharton J, White RJ, Wilt J, Wort SJ, Yung D, Lawrie A, Humbert M, Soubrier F, Trégouët DA, Prokopenko I, Kittles R, Gräf S, Nichols WC, Trembath RC, Desai AA, Morrell NW, Wilkins MR; UK NIHR BioResource Rare Diseases Consortium; UK PAH Cohort Study Consortium; US PAH Biobank Consortium.

Lancet Respir Med. 2019 Mar;7(3):227-238. doi: 10.1016/S2213-2600(18)30409-0. Epub 2018 Dec 5.

6.

In situ analysis of mTORC1/2 and cellular metabolism-related proteins in human Lymphangioleiomyomatosis.

Krencz I, Sebestyen A, Papay J, Jeney A, Hujber Z, Burger CD, Keller CA, Khoor A.

Hum Pathol. 2018 Sep;79:199-207. doi: 10.1016/j.humpath.2018.05.018. Epub 2018 Jun 6.

PMID:
29885404
7.

Comparison of Brain Natriuretic Peptide Levels to Simultaneously Obtained Right Heart Hemodynamics in Stable Outpatients with Pulmonary Arterial Hypertension.

Helgeson SA, Imam JS, Moss JE, Hodge DO, Burger CD.

Diseases. 2018 May 1;6(2). pii: E33. doi: 10.3390/diseases6020033.

8.

Sex differences in pulmonary arterial hypertension: role of infection and autoimmunity in the pathogenesis of disease.

Batton KA, Austin CO, Bruno KA, Burger CD, Shapiro BP, Fairweather D.

Biol Sex Differ. 2018 Apr 18;9(1):15. doi: 10.1186/s13293-018-0176-8. Review.

9.

Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.

Burger CD, Ozbay AB, Lazarus HM, Riehle E, Montejano LB, Lenhart G, White RJ.

J Manag Care Spec Pharm. 2018 Aug;24(8):834-842. doi: 10.18553/jmcp.2018.17391. Epub 2018 Feb 13.

10.

Prostacyclin Use Among Patients with Pulmonary Arterial Hypertension in the United States: A Retrospective Analysis of a Large Health Care Claims Database.

Burger CD, Pruett JA, Lickert CA, Berger A, Murphy B, Drake W 3rd.

J Manag Care Spec Pharm. 2018 Mar;24(3):291-302. doi: 10.18553/jmcp.2017.17228. Epub 2017 Dec 18.

11.

Multidisciplinary Perioperative Management of Pulmonary Arterial Hypertension in Patients Undergoing Noncardiac Surgery.

Díaz-Gómez JL, Ripoll JG, Mira-Avendano I, Moss JE, Divertie GD, Frank RD, Burger CD.

South Med J. 2018 Jan;111(1):64-73. doi: 10.14423/SMJ.0000000000000755.

PMID:
29298372
12.

Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes.

Burger CD, Ghandour M, Padmanabhan Menon D, Helmi H, Benza RL.

Clinicoecon Outcomes Res. 2017 Nov 24;9:731-739. doi: 10.2147/CEOR.S119117. eCollection 2017. Review.

13.

The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease.

Bajwa AA, Shujaat A, Patel M, Thomas C, Rahaghi F, Burger CD.

Pulm Circ. 2017 Feb 1;7(1):82-88. doi: 10.1086/689291. eCollection 2017 Mar.

14.

Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus document.

Rahaghi FF, Alnuaimat HM, Awdish RLA, Balasubramanian VP, Bourge RC, Burger CD, Butler J, Cauthen CG, Chakinala MM, deBoisblanc BP, Eggert MS, Engel P, Feldman J, McConnell JW, Park M, Sager JS, Sood N, Palevsky HI.

Pulm Circ. 2017 Jul-Sep;7(3):702-711. doi: 10.1177/2045893217721695. Epub 2017 Aug 22.

15.

A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.

Lu C, Lee HS, Pappas GP, Dilling DF, Burger CD, Shifren A, Veeraraghavan S, Chapman JT, Parambil J, Ruoss SJ, Young LR, Hammes SR, Kopras EJ, Roads T, Krischer JP, McCormack FX; Trial of an Aromatase Inhibitor in Lymphangioleiomyomatosis Group.

Ann Am Thorac Soc. 2017 Jun;14(6):919-928. doi: 10.1513/AnnalsATS.201610-824OC.

PMID:
28570161
16.
17.

Thyroid disease in pulmonary hypertension: Strange bedfellows?

Burger CD.

J Heart Lung Transplant. 2016 Dec;35(12):1414-1415. doi: 10.1016/j.healun.2016.06.011. Epub 2016 Jun 28. No abstract available.

PMID:
27431752
18.

The evolution of prostacyclins in pulmonary arterial hypertension: from classical treatment to modern management.

Burger CD, D'Albini L, Raspa S, Pruett JA.

Am J Manag Care. 2016 Jan;22(1 Suppl):S3-15. Review.

19.

Cardiopulmonary exercise testing in patients with pulmonary hypertension: clinical recommendations based on a review of the evidence.

Pinkstaff SO, Burger CD, Daugherty J, Bond S, Arena R.

Expert Rev Respir Med. 2016;10(3):279-95. doi: 10.1586/17476348.2016.1144475. Epub 2016 Feb 6. Review.

PMID:
26789612
20.

Prevalence of metabolic syndrome in patients with pulmonary hypertension.

Ussavarungsi K, Thomas CS, Burger CD.

Clin Respir J. 2017 Nov;11(6):721-726. doi: 10.1111/crj.12406. Epub 2015 Nov 9.

PMID:
26493968

Supplemental Content

Loading ...
Support Center